Spruce Biosciences Inc. (SPRB)
NASDAQ NASDAQ Primary 
Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy
Spruce Biosciences offers a high-risk, high-reward opportunity as it advances TA-ERT, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. TA-ERT demonstrated durable normalization of key biomarkers and stabilization of cognitive and motor function over six years, supporting its accelerated approval pathway. SPRB is preparing a BLA submission in Q4, with FDA feedback suggesting acceptance of CSF HS-NRE as a surrogate endpoint; no further clinical studies are expected pre-submission.
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 181.2% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Spruce Biosciences shares pop after FDA grants Breakthrough Therapy Designation for rare disease treatment
Spruce Biosciences (NASDAQ:SPRB) shares surged more than 390% to around $43 following news that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for its tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB). The designation recognizes the potential of TA-ERT as a first disease-modifying therapy for this ultra-rare and fatal genetic disorder.
Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)
Spruce Biosciences, Inc. (NASDAQ:SPRB ) Corporate Update Conference Call April 15, 2025 8:30 AM ET Company Participants Samir Gharib - President and CFO Javier Szwarcberg - CEO Kirk Ways - Chief Medical Officer Conference Call Participants Joe Schwartz - Leerink Partners Jon Wolleben - JMP Leland Gershell - Oppenheimer Ram Selvaraju - H.C. Wainwright Operator Welcome to the Spruce Biosciences Investor Call [Operator Instructions].
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spruce Biosciences to wind down investment for genetic disorder drug
Spruce Biosciences said on Tuesday it will wind down investments for its genetic disorder drug after it failed to meet the main goal in a mid-stage study.
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates
Spruce Biosciences, Inc. (SPRB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago.
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
